Cargando…
Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
Neuroendocrine tumors (NETs) are highly vascularized malignancies in which angiogenesis may entail cell proliferation and survival. Among the emerging compounds with antivascular properties, cabozantinib (CAB) appeared promising. We analyzed the antitumor activity of CAB against NETs utilizing in vi...
Autores principales: | Cella, Chiara Alessandra, Cazzoli, Riccardo, Fazio, Nicola, De Petro, Giuseppina, Gaudenzi, Germano, Carra, Silvia, Romanenghi, Mauro, Spada, Francesca, Grossi, Ilaria, Pallavicini, Isabella, Minucci, Saverio, Vitale, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644769/ https://www.ncbi.nlm.nih.gov/pubmed/37855330 http://dx.doi.org/10.1530/ERC-23-0232 |
Ejemplares similares
-
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021) -
Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810
por: Colzani, Mara, et al.
Publicado: (2014) -
SMYD3 promotes the epithelial–mesenchymal transition in breast cancer
por: Fenizia, Claudio, et al.
Publicado: (2019) -
Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature
por: Labrecque, Mark P., et al.
Publicado: (2021) -
Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)